THE PRODUCT SUMMARY FILE (PSF) FOR A FOOT-AND-MOUTH DISEASE VACCINE
3.E.1 Clinical studies information (additional laboratory and/or field studies to those provided in sections 3B and 3C) 1. Clinical trials sponsored by the applicant A list should be provided of all clinical trials performed in all countries that are relevant to the application for prequalification. These should include all studies sponsored by the applicant both before and at any time after initial product authorisation, whether or not submitted previously to the NRA(s) where the product is licensed. For each study on the list, there should be an indication of whether the study complied or not with GLP, GCP or any other relevant quality standard. Copies of all publications and abstracts relating to these trials should accompany the submission. In addition, the applicant should list any trials that are known to be currently ongoing, with a summary of details of the study plan and expected date of results. 1.1 Laboratory study For each study, the following information should be provided: a. a summary; b. the name of the organization/facility who conducted the studies; c. a detailed experimental protocol giving a description of the methods, apparatus and materials used, details such as species or breed of animals, categories of animals, where they were obtained, their identification and number, the conditions under which they were housed and fed (stating, inter alia, whether they were free from any specified pathogens and/or specified antibodies, the nature and quantity of any additives contained in the feed), dose, route, schedule and dates of administration, a description and a justification of the statistical methods used; d. in the case of control animals, whether they received a placebo or no treatment; e. in the case of treated animals and where appropriate, whether they received the test product or another product; f. all general and individual observations and results obtained (with averages and standard deviations), whether favorable or unfavorable. The data shall be described in sufficient detail to allow the results to be critically evaluated independently of their interpretation by the author. The raw data shall be presented in tabular form. By way of explanation and illustration, the results may be accompanied by reproductions of recordings, photomicrographs or other relevant information; g. the nature, frequency and duration of any observed adverse reactions; h. the number of animals withdrawn prematurely from the studies and reasons for such withdrawal;
19
